
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is attractive because its post-consumer separation business is now concentrated in higher-quality Innovative Medicines and MedTech franchises, improving focus, productivity, and margin potential across a global platform serving 350MM patients annually. The drug portfolio is supported by strong momentum in immunology, oncology, and neuroscience, with Tremfya, Darzalex, Icotyde, Caplyta, and Spravato helping offset Darzalex pricing headwinds in EMEA and Stelara erosion, while the pipeline still offers five +$5B and 12 +$1B revenue opportunities. Its MedTech base adds diversification and growth optionality, and management expects 2027 sales growth to be similar to 2026 after adjustments, with EPS growth trending ahead of sales growth, reinforcing the view of a defensive, cash-generative compounder.
Bears say
Johnson & Johnson is facing a negative outlook because its organic revenue growth looks vulnerable to lower-than-expected innovative medicine pipeline contributions, faster loss of exclusivity on key drugs such as Stelara and Xarelto, and uncertain traction from assets like Tremfya, Carvykti, Rybrevant, TARIS, nipocalimab, and milvexian. MedTech is also a risk as competitive headwinds, surgical robotics uncertainty, and weaker product uptake could limit growth, while management has already trimmed FY OpM guidance to about 75bps below 2025 after Firefly and Sail. On top of that, ongoing talc and other product-liability litigation, higher settlement costs, M&A integration risk, and drug-pricing pressure could further erode margins and cash flow.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares